Recruiting
Vitiligo+2
RecruitingInvestigationalNo placebo
Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials
InvestigationalNo placebo
- Disease:VitiligoNeurodermatitis+1
- Substances:Povorcitinib4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Povorcitinib
- Sponsor:Incyte Corp.
